1-3 of 3
Denis Lacombe
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

Free
Martin J. van den Bent, Hendrikus J. Dubbink, Yannick Marie, Alba A. Brandes, Martin J.B. Taphoorn, Pieter Wesseling, Marc Frenay, Cees C. Tijssen, Denis Lacombe, Ahmed Idbaih, Ronald van Marion, Johan M. Kros, Winand N.M. Dinjens, Thierry Gorlia, Marc Sanson
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (5): 1597–1604.
https://doi.org/10.1158/1078-0432.CCR-09-2902
Published: 28 February 2010
View articletitled, IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
Open the PDF for IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group in another window
Journal Articles

Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041)

Free
Hanneke W.M. van Laarhoven, Walter Fiedler, Ingrid M.E. Desar, Jack J.A. van Asten, Sandrine Marréaud, Denis Lacombe, Anne-Sophie Govaerts, Jan Bogaerts, Peter Lasch, Johanna N.H. Timmer-Bonte, Antonio Lambiase, Claudio Bordignon, Cornelis J.A. Punt, Arend Heerschap, Carla M.L. van Herpen
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (4): 1315–1323.
https://doi.org/10.1158/1078-0432.CCR-09-1621
Published: 15 February 2010
View articletitled, Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041)
Open the PDF for Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041) in another window
Journal Articles

Phase I Combining a P-Glycoprotein Inhibitor, MS209, in Combination with Docetaxel in Patients with Advanced Malignancies

Free
Véronique Diéras, Jacques Bonneterre, Valérie Laurence, Marian Degardin, Jean-Yves Pierga, Marie-Edith Bonneterre, Sandrine Marreaud, Denis Lacombe, Pierre Fumoleau
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (17): 6256–6260.
https://doi.org/10.1158/1078-0432.CCR-04-2316
Published: 06 September 2005
View articletitled, Phase I Combining a P-Glycoprotein Inhibitor, MS209, in Combination with Docetaxel in Patients with Advanced Malignancies
Open the PDF for Phase I Combining a P-Glycoprotein Inhibitor, MS209, in Combination with Docetaxel in Patients with Advanced Malignancies in another window